Worsening of motor features of parkinsonism with olanzapine

Movement Disorders

Volumn 14, Issue 6, 1999, Pages 1014-1016

  Molho, Eric S ^a   Factor, Stewart A ^a,b  

^a ALBANY MEDICAL COLLEGE   (United States)

^b ALBANY MEDICAL CENTER   (United States)

Author keywords

Olanzapine; Parkinsonism; Psychosis

Indexed keywords

CLOZAPINE; LEVODOPA; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; PARKINSONISM; PRIORITY JOURNAL; PSYCHOSIS; RETROSPECTIVE STUDY;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; MOTOR SKILLS; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; PARKINSON DISEASE, SECONDARY; PIRENZEPINE; PSYCHOSES, SUBSTANCE-INDUCED; RISK FACTORS;

EID: 0032752941     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(199911)14:6<1014::AID-MDS1017>3.0.CO;2-9     Document Type: Article

References (16)

1. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 1993;43:2227-2229.
2. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 1995;45:669-671.
3. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov Disord 1997;12:483-496.
4. The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-763.
5. Livingston MG. Risperidone. Lancet 1994;343:457-460.
6. Ford B, Lynch T, Greene P. Risperidone in Parkinson's disease [Letter]. Lancet 1994;344:681.
7. Rich SS, Friedman JH, Ott BR. Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic-rigid syndromes. J Clin Psychiatry 1995;56:556-559.
8. Wolters ECh, Jansen ENH, Tuynman-Qua HG, Bergmans PLM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 1996;47:1085-1087.
9. Friedman JH. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease [Letter]. Neurology 1998;50:1195-1196.
10. Friedman JH, Goldstein S, Jacques C. Substituting clozapine for Olanzapine in psychiatrically stable Parkinson's disease patients: results of an open-label pilot study. Clin Neuropharmacol 1998; 21:285-288.
11. Jimenez-Jimenez FJ, Tallon-Barranco A, Orti-Pareja M, Zurdo M, Porta J, Molina JA. Olanzapine can worsen parkinsonism. Neurology 1998;50:1183-1184.
12. Graham JM, Sussman JD, Ford KS, Sagar HJ. Olanzapine in the treatment of hallucinosis in idiopathic Parkinson's disease: a cautionary note. J Neurol Neurosurg Psychiatry 1998;65:774-777.
13. Weiner WJ, Minagar A, Shulman LM. Olanzapine for the treatment of hallucinations/delusions in Parkinson's disease. Mov Disord [Abstract]. 1998;13(suppl 2):62.
14. Bymaster FP, Rasmussen K, Calligaro DO, et al. In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry 1997;58(suppl 10):28-36.
15. Moore NA, Leander JD, Benvenga MJ, Gleason SD, Shannon H. Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry 1997;58(suppl 10):37-44.
16. Wolters EC, Jansen ENH, Tuynman-Qua HG, Bergmans PLM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease [Letter]. Neurology 1998;1196.